Literature DB >> 34030176

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans.

Jackson S Turner1, Wooseob Kim1, Elizaveta Kalaidina2, Charles W Goss3, Adriana M Rauseo4, Aaron J Schmitz1, Lena Hansen1,5, Alem Haile6, Michael K Klebert6, Iskra Pusic7, Jane A O'Halloran4, Rachel M Presti4,8, Ali H Ellebedy9,10,11.   

Abstract

Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1-7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-28-10. Nonetheless, it has been reported that levels of anti-SARS-CoV-2 serum antibodies decrease rapidly in the first few months after infection, raising concerns that long-lived BMPCs may not be generated and humoral immunity against SARS-CoV-2 may be short-lived11-13. Here we show that in convalescent individuals who had experienced mild SARS-CoV-2 infections (n = 77), levels of serum anti-SARS-CoV-2 spike protein (S) antibodies declined rapidly in the first 4 months after infection and then more gradually over the following 7 months, remaining detectable at least 11 months after infection. Anti-S antibody titres correlated with the frequency of S-specific plasma cells in bone marrow aspirates from 18 individuals who had recovered from COVID-19 at 7 to 8 months after infection. S-specific BMPCs were not detected in aspirates from 11 healthy individuals with no history of SARS-CoV-2 infection. We show that S-binding BMPCs are quiescent, which suggests that they are part of a stable compartment. Consistently, circulating resting memory B cells directed against SARS-CoV-2 S were detected in the convalescent individuals. Overall, our results indicate that mild infection with SARS-CoV-2 induces robust antigen-specific, long-lived humoral immune memory in humans.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34030176     DOI: 10.1038/s41586-021-03647-4

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1 in total

1.  Health care issues given short shrift in US election campaigns.

Authors:  C Gray
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

  1 in total
  155 in total

1.  Rapid decay of anti-SARS-CoV-2 antibodies in infection-naïve healthcare workers four months after vaccination.

Authors:  Maria Stamatopoulou; Vasileios Tsamadias; Theodosios Theodosopoulos; Stiliani Demeridou; George Kaparos; Nikolaos Memos; Manoussos Konstadoulakis; Stavroula Baka
Journal:  Germs       Date:  2021-12-29

2.  RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein.

Authors:  Juha-Pekka Mattila; Arlene Amaro; Monica Longo; James Antaki; Sanam Koirala; Alberto Gandini
Journal:  Biomicrofluidics       Date:  2022-03-17       Impact factor: 2.800

3.  SARS-CoV-2 infection generates tissue-localized immunological memory in humans.

Authors:  Maya M L Poon; Ksenia Rybkina; Yu Kato; Masaru Kubota; Rei Matsumoto; Nathaniel I Bloom; Zeli Zhang; Kathryn M Hastie; Alba Grifoni; Daniela Weiskopf; Steven B Wells; Basak B Ural; Nora Lam; Peter A Szabo; Pranay Dogra; Yoon S Lee; Joshua I Gray; Marissa C Bradley; Maigan A Brusko; Todd M Brusko; Erica O Saphire; Thomas J Connors; Alessandro Sette; Shane Crotty; Donna L Farber
Journal:  Sci Immunol       Date:  2021-11-19

4.  Uninformative and unuseful: why it is necessary to actively challenge COVID-19 antibody testing postvaccination.

Authors:  D Romero-Alvarez; D F López-Cevallos; I Torres
Journal:  Public Health       Date:  2021-08-25       Impact factor: 2.427

Review 5.  The humoral response and antibodies against SARS-CoV-2 infection.

Authors:  Hai Qi; Linqi Zhang; Bo Liu; Xinquan Wang
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

6.  Primary Immune Response Provides Protective Efficacy against SARS-CoV-2 Reinfection.

Authors:  Rupendra Shrestha; Reena Shrestha; Ram Bahadur Khadka; Rabin Gyawali
Journal:  JNMA J Nepal Med Assoc       Date:  2021-07-30       Impact factor: 0.556

Review 7.  The success of SARS-CoV-2 vaccines and challenges ahead.

Authors:  Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2021-07-14       Impact factor: 21.023

8.  Beyond neutralization for BNT162b2 mRNA vaccination.

Authors:  Payal Damani-Yokota; Stephen T Yeung; Kamal M Khanna
Journal:  Cell Host Microbe       Date:  2021-07-14       Impact factor: 31.316

9.  Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.

Authors:  Sandra Scheiblhofer; Stephan Drothler; Werner Braun; Reinhard Braun; Maximilian Boesch; Richard Weiss
Journal:  Vaccine       Date:  2021-06-26       Impact factor: 4.169

10.  Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.

Authors:  Kristen W Cohen; Susanne L Linderman; Zoe Moodie; Julie Czartoski; Lilin Lai; Grace Mantus; Carson Norwood; Lindsay E Nyhoff; Venkata Viswanadh Edara; Katharine Floyd; Stephen C De Rosa; Hasan Ahmed; Rachael Whaley; Shivan N Patel; Brittany Prigmore; Maria P Lemos; Carl W Davis; Sarah Furth; James B O'Keefe; Mohini P Gharpure; Sivaram Gunisetty; Kathy Stephens; Rustom Antia; Veronika I Zarnitsyna; David S Stephens; Srilatha Edupuganti; Nadine Rouphael; Evan J Anderson; Aneesh K Mehta; Jens Wrammert; Mehul S Suthar; Rafi Ahmed; M Juliana McElrath
Journal:  Cell Rep Med       Date:  2021-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.